Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pyridoxal phosphate (PLP) is the metabolically active form of vitamin B6, serving as an essential coenzyme for over 140 biochemical reactions, including amino acid metabolism and the biosynthesis of neurotransmitters such as gamma-aminobutyric acid (GABA), dopamine, and serotonin. In clinical practice, PLP is administered to treat rare genetic disorders like pyridoxal 5′-phosphate-binding protein (PLPBP) deficiency and pyridoxine-dependent epilepsy, where patients cannot effectively utilize or maintain levels of the active cofactor. By providing the active form directly, PLP bypasses metabolic blocks in the B6 activation pathway, helping to control refractory seizures and improve neurological outcomes in affected individuals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pyridoxal phosphate.